BACKGROUND: Introduction of human papillomavirusebased screening is ongoing in many countries, given its higher sensitivity and longer-lasting protection compared with cytology-based screening. However, optimal clinical management of human papillomavirusepositive but cytology-negative women is unclear, and additional studies with clinical follow-up are warranted. OBJECTIVE: The aim of the current study was to investigate the longterm outcomes of the clinical management used in a double-blind, randomized clinical trial of human papillomavirus screening conducted in the context of the routine, organized screening program in Sweden. STUDY DESIGN: Among 12,527 women aged 32e38 years enrolled in the trial, we followed up the 195 women who attended the colposcopy screening who were cytologically normal but persistently human papillomavirus positive (at least 12 months later; median, 19 months) in the human papillomavirus testing arm (n ¼ 100) or were randomly selected from the control arm (n ¼ 95). Women in the human papillomavirus testing arm were followed up with repeated human papillomavirus testing, cytologies, and colposcopies if persistently human papillomavirusepositive without cervical intraepithelial neoplasia grade 2 or worse. A similar number of random colposcopies and tests were carried out in the control arm. Women were followed up over 13 years for the main outcome
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Key words: cervical intraepithelial neoplasia, colposcopy, human papillomavirus, long term-follow-up, randomized clinical trial C ytological screening every 3e5 years reduces the cervical cancer risk by about 80% in countries with organized screening programs through early detection and treatment of precursor lesions (cervical intraepithelial neoplasia [CIN]). 1, 2 Clinical management of women includes referral to colposcopy, colposcopically directed biopsies, surgical removal of histologically verified high-grade lesions and posttreatment follow-up. 1 Human papillomavirus (HPV) is the major cause of cervical cancer. 3 HPV-based screening is more sensitive than cytology in detecting CIN grade 2 or worse (CIN2þ), providing a greater and more long-lasting protection against invasive disease. [4] [5] [6] [7] However, the optimal clinical management of women who screen HPV positive but cytology negative is unclear. 8 Persistent infection with high-risk (HR) HPV is necessary for the development of cervical cancer. 9, 10 Most infections are transient, but women with a persistent infection have a high risk for development of CIN2þ and cervical cancer. 11, 12 The HPV screening trial Swedescreen was nested in the population-based, organized cervical cancer screening program in Sweden. The clinical management of HPV-positive, cytology-negative women was a repeat HPV test at least 12 months later and, if type-specific HPV persistence was found, referral to colposcopy with colposcopically directed biopsies and endocervical cytology. In case of normal colposcopy 2 blind cervical biopsies were taken. At the first study colposcopy, 28 of 100 women with HPV persistence in the intervention arm and 2 of 95 women selected at random from the control arm had CIN2þ. 13 If women were not treated for CIN2þ, they were invited for repeat yearly HPV testing and were, if persistently HPV positive, invited to an additional colposcopy.
The aim of the present study was to evaluate the long-term outcome of the clinical management of these women, using comprehensive nationwide linkages with the nationwide Swedish cervical screening registry.
Materials and Methods

Study population and data
The Swedescreen population-based randomized clinical trial (RCT) of primary Since 1997, the trial participants have been followed up with registry linkages. Using unique personal identification numbers, linkages to the Swedish National Cervical Screening Registry (NKCx) have been performed up to December 2012 to identify all histological endpoints occurring among study participants, regardless of whether the histological endpoint was the result of study colposcopies. Until the primary endpoint of the study was reached (protection against CIN2þ in a second screening round), all histopathologies were rereviewed by an expert pathologist. 13 For the long-term follow-up after this point, routine histopathological diagnoses were used and identified through linkage to the NKCx. The current analysis makes use of the re-reviewed histopathologies from the active study period and routine histopathological diagnoses that were obtained for lesions occurring outside the study colposcopies and during the long-term follow-up.
Randomization and masking
In total, 12,527 women were enrolled, following informed consent, and randomized 1:1 to HPV and cytology double testing (intervention arm, n ¼ 6257) or cytology only (control arm, n ¼ 6270). Women were randomized using computer-generated random numbers by an independent institute (the Cancer Registry of Stockholm). Further details on the study protocol have been published previously.
14 Both the study participants and the colposcopists were blinded to the women's HPV status. The trial was unblinded in August 2003, after the completion of the first study colposcopies and 3 years after recruitment concluded.
Intervention
HPV DNA testing For all women, a Papanicolaou smear and a brush sample for HPV DNA testing were collected. All samples were analyzed in the intervention arm as well as a random sample of the control arm. HPV DNA testing was conducted using polymerase chain reaction with GP5þ/ 6þ polymerase chain reaction primers and subsequent typing with reverse dotblot hybridization. The assay correlated well to the HPV assay used in other clinical validation studies. 15 Colposcopy follow-up In the intervention arm, women who were HPV positive and cytology negative at enrollment were invited for a second HPV test at least 12 months later (median actual attendance, 19 months; interquartile range, 15e27 months). At baseline, 433 women were HPV positive, of which 341 were cytology negative and therefore invited to a second HPV test. A total of 270 women attended the second HPV test, of which 119 women (44%) had type-specific HPV persistence and were subsequently invited to colposcopy (100 women attended). 13 In the control arm, 111 women were selected at random for mock HPV testing and subsequent colposcopies to control for ascertainment bias (95 women attended). The results of the first study colposcopies have been published. 13 Following the first study colposcopy, women who had not been treated for CIN2þ were invited for yearly repeat HPV tests. Throughout the study, all cytological abnormalities were managed according to the routine procedures used in the Swedish organized screening program. Women with continuous typespecific HPV persistence as well as a similar number of randomly chosen control women were invited for additional colposcopies (Figure 1 ). Subsequent colposcopies were performed according to the same protocol and conducted by the same gynecologists as the first study colposcopies, except that HPV test results were unblinded.
The protocol included an examination of the transformation zone for visibility, maturation, and epithelial changes. Five percent acetic acid was applied to identify undifferentiated epithelia or inflammation as well as CIN.
The dimension and border of abnormal areas were assessed by application of 5% potassium iodine to the ectocervix. All acetowhite areas, including metaplasia (undifferentiated epithelium), inflammation, and neoplasia were considered as abnormal colposcopies and biopsied. The endocervix was sampled with a cytobrush. 16 Blind biopsies were taken at 12 o'clock and 6 o'clock on the ectocervix close to the squamocolumnar junction if the colposcopy was considered to be normal, according to standard protocol at the time. 13 Treatment and further management of the women based on the results of cytologies and histopathologies followed the routine procedures of the screening program.
Statistical analysis
The 195 women who attended the first study colposcopies were followed up using registry linkages. The start of the follow-up was the date of the first test in the RCT. The first instance of histologically confirmed CIN2þ or CIN3þ were identified through the study colposcopies and linkages to the NKCx. Women were censored at the last registered testing date, which is appropriate for screen-detected disease. There were no cases of invasive disease found during follow-up in either arm.
Linkages to the Swedish population registry found that 191 of 195 women were alive and resident in Sweden throughout the follow-up. Two women were deceased (both in the intervention arm) and 2 women had emigrated. All 195 women were alive and resident in Sweden for >5 years. Women were categorized as having a known persistence status (time frame determined as a positive HPV test result plus 1 year for the analysis), unknown persistence status (no HPV test performed 1 year after the last HPV test; in other words, more than 1 year since the last HPV test was taken), HPV type-specific clearance after persistence, and HPV negativity after persistence. Women who switched types were persistently positive for one type and then at a subsequent test were negative for the initial type but positive for a new type.
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Absolute risks for CIN2þ and CIN3þ were calculated for the entire follow-up period (13 years). Cumulative incidence proportions of CIN2þ and CIN3þ were estimated using 1 minus the Kaplan-Meier curves.
All analyses were completed using STATA 11 (StataCorp, College Station, TX). The Swedescreen study was approved by the ethical review board in Stockholm, Sweden (DNR 1996/305). The long-term follow-up of the Swedescreen study had an additional approval from the ethical review board in Stockholm, Sweden (DNR 2012/780-32).
Results
In total, 195 women with a normal cytology attended the first study colposcopies (100 women in the intervention arm with persistent HR HPV infection and 95 randomly selected women from the control arm). The CIN2þ cases detected at the first study colposcopy have previously been described. 13 During the long-term follow-up (up to 13 years), linkages were made to the national screening registry NKCx.
All 195 women were found to have had additional cytologies in the national registry (mean number of cytologies, 8; range, 4e17) and 192 of 195 of the biopsies from the per-protocol colposcopies were identified in the registry (mean number of cervical histopathologies, 2; range, 1e9). An additional 25 CIN2þ diagnoses occurred in the intervention arm, but no further CIN2þ occurred in the control arm.
Among the 102 women with initial HR HPV type-specific persistence (all 100 women in the intervention arm and 2 among the randomly selected women in the control arm), the absolute risk for CIN2þ over the long-term follow-up was 54% (55 of 102, 95% confidence interval [CI], 44e63%) and the risk for CIN3þ was 32% (33 of 102, 95% CI, 24e42%). By study arm, the risks for CIN2þ was 54% in the intervention arm and 2% in the control arm (log rank value of P < .001).
Persistence by type was as follows: 25 women with HPV 16, 11 with HPV18, 31 with HPV 31, with 6 HPV 33, 9 with HPV 45, and 20 with other HR HPV (not shown). Among the 25 women with a type 16 persistence, 68% (17 of 25, 95% CI, 48e83%) and 56% (14 of 25, 95% CI, 37e73%) developed CIN2þ and CIN3þ, respectively (not shown). Persistence with HPV16 conferred the highest risk for CIN2þ followed by HPV 18 (7 of 11, 64% [95% CI, 35e85%]), The cumulative incidence proportion of CIN2þ increased steadily in the intervention arm in the first 6 years of follow-up. However, after 6 years, only 3 additional cases of CIN2þ occurred (Figure 2 ). For CIN3þ, the pattern was similar, with only 1 additional case occuring after 6 years ( Figure 3) . Among the 40 women who attended repeat testing and were known to be continuously HPV persistent, all 40 of 40 developed CIN2þ within 7 years of the baseline HPV-positive test result ( Figure 4) ; 63% (95% CI, 48e77%) and 98% (95% CI, 89e100%) had developed CIN2þ at CIN3þ after 6 years of followup, respectively.
The risks for women who had not attended a yearly repeat test and had an unknown persistence status were similar to the risk seen for all women who had had persistence at baseline (50% developed CIN2þ within 7 years) (Figure 4) . In this group, 11% (95% CI, 4e31%) and 46% (95% CI, 29e66%) developed CIN2þ at CIN3þ after 6 years of followup, respectively. None of the women who had initially had HPV persistence developed CIN2þ following a negative HPV test (clearance, n ¼ 31) or following a type switch (n ¼ 4) (Figure 4 ).
Comment
Our results provide evidence of a very high long-term risk of CIN2þ among women with continuous HPV persistence, even with an initially negative cytology and negative colposcopically directed biopsies. We also provide evidence that women who had had HPV persistence but have become HPV negative are not at measurable long-term risk of CIN2þ. We find that women with HPV persistence over 7 years either develop CIN2þ or become HPV negative.
If HPV-based primary screening had identified a group of continuously HPV-positive women who do not develop any treatable lesions and may need very long-term clinical follow-up, this would have been a significant burden. However, because all of the women with continuous HPV
FIGURE 2
Cumulative proportion of CIN2D in Swedescreen study over 13 years
The cumulative incidence proportion of CIN2þ in the intervention (gray line) and control (black line) arms of the Swedescreen study over 13 years of follow-up.
CIN2þ, cervical intraepithelial neoplasia grade 2 or worse.
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FIGURE 3
Cumulative proportion of CIN3D in the Swedescreen study over 13 years
The cumulative incidence proportion of CIN3þ in the intervention (grey line) and control (black line) arms of the Swedescreen study over 13 years of follow-up. ajog.org
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persistence developed CIN2þ and because no cases were seen among women with HPV clearance, continued follow-up of women with HPV persistence after 7 years does not appear to be required. Although our numbers are small, it seems that HPV 16 carries a particularly high risk for CIN2þ and CIN3þ when persistent, suggesting that women with HPV 16 persistence could be a priority. The fact that the CIN2þ lesions continued to appear for 7 years during intensive clinical follow-up, suggests that intensive clinical follow-up of women with HPV persistence is not able to prevent CIN2þ lesions from developing and merely resulted in a somewhat earlier diagnosis of these lesions (cf, Figure 4 ). This suggests that ensuring that women with HPV persistence are not lost to follow-up should be prioritized over the intensity of the clinical management.
There were no cases of invasive cancer in the cohort, regardless of whether the women had attended intensive clinical follow-up or not. Too intensive management (yearly repeat tests) may result in the result that women drop out of the followup, which, considering the very high CIN2þ risks, is potentially unsafe. More conservative management strategies with repeat tests at 3 and 6 years, but during which every effort is made to ensure a high attendance rate, may be preferable.
The Swedescreen RCT was nested within the population-based cervical screening program in Sweden. Therefore, the study participants are representative of women attending screening, and the results should be generalizable to the general screening population. Because randomly selected women from the control arm underwent the same study procedures of repeated HPV testing, endocervical cytology, colposcopy, and colposcopy-directed biopsies, verification bias is likely to be limited.
Additional strengths of the study include the extensive length of follow-up (13 years) and the fact that all women had additional tests on follow-up, identified using linkages to a nationwide and comprehensive screening registry. The population coverage of the screening program in Sweden at the 3-5 year recommended intervals is 82% and the 6 year population coverage is 91%. 17 Among women who have previously attended screening, the future coverage tends to be higher than in the general population, and the fact that all women in the trial group could be followed up is therefore not surprising.
Limitations of the study include the fact that routine histopathological results were used after the first study colposcopy. Also, several women dropped out from the yearly HPV tests offered, resulting in the fact that it is unknown whether their HPV persistence continued or whether these women had cleared their HPV. The high dropout rate and the limited benefits obtained with intensive follow-up with yearly HPV testing and extended gynecological investigations further suggest that a less intensive clinical follow-up (eg, repeat HPV testing at 3 and 6 years with referral only if continuous HPV persistence) is warranted.
A note of caution is needed, however, because the safety of such intervals is impacted by the risk of overlooked highgrade lesions at colposcopy 18 and the quality of the HPV testing performed because it cannot be assumed that all HPV tests have the same predictive ability as the HPV test used in the Swedescreen RCT. Evidence from laboratories participating in the global HPV LabNet HPV genotyping proficiency panel studies indicates that laboratory performance has improved overall, 19 but continued quality assurance and monitoring of HPV tests used in screening is needed. The very high risks for CIN2þ seen among women with continuous persistence after 6 years suggest that diagnostic conization could be considered if the colposcopy is not adequate after continuous persistence for 6 years or more.
HPV persistence has been confirmed to be consistently and significantly associated with the development of Cumulative proportion of CIN2D among women with type-specific persistence
The lines represent women with a known persistence status (black line; n ¼ 40), unknown persistence status (dashed line; n ¼ 27), HPV type switch (clearance of the previously persistent type; dotted line; n ¼ 4), and HPV negativity after persistence (dash-dot line; n ¼ 31). The last 2 lines are entirely overlapping because there were no events detected during follow-up for both the latter 2 groups.
CIN2þ, cervical intraepithelial neoplasia grade 2 or worse; HPV, human papillomavirus. Original Research GYNECOLOGY ajog.org high-grade lesions as described in a 2008 meta-analysis. 20 However, longterm persistence of HPV infections in the absence of cytological abnormalities has also been reported. 21 In that study, no comment on management was given. 21 A population-based study in Colombia focusing on women who were cytology negative at baseline and examining prevalent and incident HPV infections and risk for high-grade lesions showed that HPV type 16 persistence carried a particularly high risk for CIN2/3. 22 Data from the Guanacaste population-based cohort study reflects our finding that very few infections persist without the development of a CIN2þ lesion and highlights the importance of duration of infection. 23 Compared with our publication of the results from the first study colposcopies, 13 this long-term follow-up provides further evidence on the clinical management of cytologynegative and persistently HPVpositive women.
Additionally, this analysis provides 13 years of follow-up for this subcohort of the Swedescreen trial, demonstrating the long-term risk for CIN2þ by persistence status and in the context of an intensive clinical follow-up of women with HPV persistence. In our material, we found that women who clear HPV persistence were not at a measurable risk of CIN2þ. Although this suggests that these women may be safely returned to routine screening, reappearance of an HPV infection is possible, and treated women may still be at risk for reinfection and repeated CIN2þ. 24 Whereas following up women with HPV persistence (having an increased risk for high-grade lesions) is more easily facilitated by an organized program, this issue can be solved in context-specific ways, depending on the clinician or health care unit responsible for care and the design of medical chart information systems. In low-resource settings, baseline testing is possible, but persistence testing poses additional challenges because follow-up over time may be limited by health care infrastructures.
In conclusion, the evidence of a very high 7 year risk of developing CIN2þ among women with continuous HPV persistence, even with an initially negative cytology, indicates that follow-up for this length of time is a priority.
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